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Abstract
Transplant arteriosclerosis is characterized by inflammation and intimal thickening caused by accumulation of smooth
muscle cells (SMCs) both from donor and recipient. We assessed the relationship between clinical factors and the presence
of host-derived SMCs in 124 myocardial biopsies from 26 consecutive patients who received hearts from opposite-sex
donors. Clinical and demographic information was obtained from the patients’ medical records. Host-derived SMCs
accounted for 3.3562.3% of cells in arterioles (range, 0.08–12.51%). As shown by linear regression analysis, an increased
number of SMCs was associated with rejection grade (mean, 1.4161.03, p=0.034) and the number of leukocytes (19.1612.7
per 20 high-power fields, p=0.01). The accumulation of host-derived SMCs was associated with an increased number of
leukocytes in the allografts. In vitro, monocyte chemoattractant protein 1 (MCP-1) released from leukocytes was crucial for
SMC migration. After heart allotransplantion, mice treated with MCP-1-specific antibodies had significantly fewer host-
derived SMCs in the grafts than mice treated with isotypic antibody controls. We conclude that the number of host-derived
SMCs in human cardiac allografts is associated with the rejection grade and that MCP-1 may play pivotal role in recruiting
host-derived SMCs into cardiac allografts.
Citation: Religa P, Grudzinska MK, Bojakowski K, Soin J, Nozynski J, et al. (2009) Host-Derived Smooth Muscle Cells Accumulate in Cardiac Allografts: Role of
Inflammation and Monocyte Chemoattractant Protein 1. PLoS ONE 4(1): e4187. doi:10.1371/journal.pone.0004187
Editor: Per Westermark, Uppsala University, Sweden
Received June 3, 2008; Accepted December 5, 2008; Published January 14, 2009
Copyright:  2009 Religa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Science Research Committee MNiSW 3B138, Swedish Research Council (K2004-16X-12615-07A, K2007-56X-
12615-10-3), the Swedish Society of Medicine (2003-633), the Tobias Foundation (28/03 and 29/04), and the Heart and Lung Foundation (199941305, 200241138,
20030055, and 20050266). King Gustaf V’s 80-Year Anniversary Foundation, Swedish Cancer Foundation (060253), and Children’s Cancer Foundation (05/100). C.S.-
N. is a Royal Swedish Academy of Science Research Fellow supported by a grant from the Knut and Alice Wallenberg Foundation. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: piotr.religa@ki.se
. These authors contributed equally to this work.
Introduction
The major cause of late organ dysfunction after transplantation
is vasculopathy characterized by vessel inflammation and intimal
hyperplasia due to the recruitment of smooth muscle cells (SMCs)
into the vessel intima [1,2]. This process results in progressive
luminal narrowing caused in part by a healing reaction in the
intima. The intimal cells could be derived from phenotypically
modulated medial SMCs within the graft or from host-derived
SMCs [3]. Possible sources of the host-derived cells in cardiac
allografts are cells in adjacent vessels that migrate toward the graft,
circulating tissue progenitors, or possibly bone marrow–derived
progenitors [4–6]. Although host-derived cells contribute to
transplant vasculopathy, their clinical significance and the
mechanisms of their accumulation in the intima are unknown.
Transplant vasculopathy is believed to have both immunolog-
ical and nonimmunological causes and results in vascular
dysfunction due to factors affecting the allograft [1]. Diverse
immunological factors that contribute to chronic transplant
dysfunction have been identified, including the degree of acute
rejection, immunosuppression, and opportunistic infections, par-
ticularly cytomegalovirus infection [7,8]. Nonimmunological
factors, such as the age of the recipient, underlying diseases, and
ischemia, also contribute to chronic transplant dysfunction.
In this study, we investigated clinical factors that influence the
accumulation of host-derived cells in arterioles of human cardiac
allografts and potential factors involved in their migration. We
analyzed archived myocardial biopsies from heart transplant
recipients mismatched in sex with their donors, which enabled us
to determine the origin of SMCs in the vessel lesions. We also
performed in vitro migration assays and in vivo heart transplan-
tation studies in mice.
Materials and Methods
Biopsies of human cardiac allografts
We analyzed 124 post-transplantation cardiac biopsy specimens
from 26 consecutive patients who received cardiac allografts from
opposite-sex donors from 1994–2003. Specimens were from the
tissue bank at the Silesian Center for Heart Disease (Zabrze,
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ethics committee at the Karolinska Institute and conformed to the
principles outlined in the Declaration of Helsinki. All patients gave
informed consent. Specimens were obtained by endomyocardial
biopsy as part of a standard procedure for monitoring acute graft
rejection (weekly for the first month, every 2 weeks for the second
month, every 3 months until end of the first year, every 6 months
during the second year, and yearly thereafter). Biopsies not
containing arterioles were excluded from analysis.
Specimens were analyzed by pathologist using the criteria of the
International Society for Heart and Lung Transplantation [9].
Rejection was graded according to the following scale: 0, no
rejection; 1A, focal (perivascular or interstitial) infiltrate without
necrosis; 1B, diffuse but sparse infiltrate without necrosis; 2, a
single focus of aggressive infiltration and/or focal myocyte
damage; 3A, multifocal aggressive infiltrates and/or myocyte
damage; 3B diffuse inflammation and necrosis; and 4 diffuse
aggressive polymorphous infiltrate, edema, hemorrhage, vasculitis,
and necrosis. Samples were also analyzed by immunohistochem-
istry for the accumulation of host-derived SMCs in arterioles.
Clinical information
Retrospective clinical and demographic data were collected
from the patients’ medical records. The clinical data included age,
time from transplantation, underlying diseases (hypertension,
diabetes, smoking, gastric ulcer, hepatopathy, episodes of throm-
boembolism, heart, lung and kidney failure, cancer, hypercholes-
terolemia), and blood morphology. Information about immuno-
suppression and infection with cytomegalovirus, hepatitis B virus,
hepatitis C virus, and human immunodeficiency virus was
obtained at the time of hospitalization for myocardial biopsy. To
assess heart function, echocardiography was performed to estimate
the ejection fraction.
Immunohistochemistry
Immunohistochemistry was performed as described [10] with
primary antibodies against human smooth muscle a-actin (aSMA),
vonWillebrand factor (vWF), CD45, CD14, CD3, CD8, CD 4,
IgG and IgM (Dako, Glostrup, Denmark), MCP-1 (Biolegend, San
Diego, CA). Vessels positive for aSMA and vWF and cells positive
for CD45, CD14, CD3, CD8, and CD4 were manually counted in
20 high-power fields (HPF) and averaged. IgG and IgM levels
were scored as low, medium, or high.
Laser capture microdissection of aSMA-positive arterioles
Laser capture microdissection was performed on tissue sections
stained for aSMA. In three to four sections from each biopsy, 300–
400 aSMA-positive cells were microdissected from arterioles with
the PixCell II System (Arcturus Engineering, Mountain View,
CA). The percentage of host-derived cells among captured cells
was estimated by real-time PCR for the SRY gene as described
[10], [11].
In situ hybridization for chromosome Y
Tissue sections were rehydrated in xylene-graded ethanol,
boiled in citrate buffer for 15 min to unmask epitopes, and
incubated with anti-aSMA antibodies overnight at 4uC. After
fixation in 4% formalin in phosphate-buffered saline for 15 min,
the sections were placed in 26saline sodium citrate (SSC)/0.5 NP-
40 at 37uC for 30 min and dehydrated in 70% and 95% ethanol
for 2 min each, denatured in 70% formamide/26SSC at 72u for
20 min, and dehydrated in ice-cold ethanol. The sections were
then hybridized with 10 ml of probe for 16 h in a humidified
chamber and washed with 0.56 SSC for 5 min at 72uC, 50%
formamide/26SSC at 43uC for 15 min, and 0.16SSC at 60uC
for 15 min. Finally, the sections were counterstained with
propidium iodide, mounted in Mountex (Vector), and examined
by confocal microscopy (Leica TCS SP5).
Cell migration assay
The migration of SMCs was measured with a modified Boyden
chamber (NeuroProbe). Cells (60,000/well) were seeded into the
upper chamber in serum-free Ham’s F-12 medium containing
0.2% bovine serum albumin. Ham’s F-12 medium containing
monocyte chemoattractant protein (MCP) 1 (50 ng) or leukocyte-
conditioned medium was added to the lower chamber. In
migration inhibition experiments, we added MCP-1 antibodies
to the medium in the lower chamber or anti-CCR2 to the cells
30 min before the experiment. After a 6-h incubation, the medium
was removed, and cells attached to the bottom of the filter were
fixed in 99% methanol, stained with a Giemsa solution, and
examined by light microscopy. The mean number of cells per
microscopic field (magnification, 206) was plotted. All experi-
ments were repeated three or four times.
Mouse heart allograft transplantation
Balb mice were used as donors of vascularized cardiac allografts.
The protocol was approved by the ethics committee at Warsaw
Medical University and conformed to the principles in the
Declaration of Helsinki. The mice were anesthetized with
medetomidine (1 mg/g) and ketamine (75 mg/g), and vascular-
ized cardiac grafts were collected and transplanted into recipient
GFP mice as described [12]. The aorta and pulmonary artery of
the donor heart were anastomosed to the recipient abdominal
aorta and inferior vena cava, respectively. Allograft survival was
evaluated by daily palpation. Cessation of beating was interpreted
as rejection. Between days 5–10 after transplantation, mice
Table 1. Baseline characteristic of the patients*.
Characteristics Total Females Males
No. of patients 26 15 11
Number of biopsies (mean+range) 124 6.6 (4–14) 2.3 (1–4)
Mean age (years) 41620.0 31.5621.7 53.466.8
Treatment indication
Congestive cardiomyopathy 10 5 5
Ischemic heart diseases 13 7 6
Hypertrophic cardiomiopaty 1 1
Acquired valve disease 1 1
Cogenital heart disease 1 1
Diabetes 5 1 4
Smoking 9 4 5
Re-operation 2 0 2
Hypertension 9 4 5
Thromboembolic episodes 9 2 7
Hypercholesterolemia 16 8 8
Kidney failure 1 1 0
Gastric ulcer 2 2 0
Liver failure 2 0 2
*Values are numbers of patients, unless indicated otherwise.
doi:10.1371/journal.pone.0004187.t001
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hearts were collected, cut into 5-mm-thick sections, stained
immunohistochemically for CD45, CD68, CD3, CD8, CD4,
and aSMA, and analyzed by confocal microscopy.
Data presentation and statistical analysis
Data analyses and event classifications were performed by
investigators blinded to the clinical information. Values are
expressed as mean6SD or as means and medians with SD.
Associations between accumulation of host-derived SMCs and
predictors of cellular accumulation selected from demographical,
biochemical/functional, and immunohistochemical data were
analyzed by best-subset logistic regression. The Akaike informa-
tion criterion and manual elimination of risk factors based on
medical consideration were used to obtain a parsimonious model
with good predictive capability. Leave-one-out cross-validation
was used to avoid overfitting of the final model. The final model
included only predictors with significant contribution (p,0.05). In
all analyses, a two-sided p value,0.05 was considered significant.
The results of studies in mice were analyzed with t tests; p,0.05
was considered significant.
Results
Patient characteristics
Myocardial biopsies were obtained from 26 consecutive patients
who received cardiac transplants from donors of the opposite sex.
The characteristics of the patients and the indications for
transplantation are shown in Table 1. There were 15 women
and 11 men (mean age, 41 years). The most common indications
Figure 1. Immunohistochemical characteristic of human cardiac allografts. (A) Immunohistochemistry for aSMA (blue) followed by in situ
hybridization for chromosome Y (green) and nuclear counterstaining (red). (B–K) Immunohistochemical staining of human cardiac allografts for aSMA
(B), vWF (C), CD45 (D), CD14 (E), IgG (F), IgM (G), CD4 (H), and CD8 (I). Arrows indicate positive cells and staining. (J and K) Scatter plots showing the
association between the number of aSMA-positive cells in the vessel and patient age (J) CD45+ cells (K).
doi:10.1371/journal.pone.0004187.g001
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congestive cardiomyopathy (n=10). The patients were character-
ized by hypercholesterolemia (n=16), smoking (n=9), hyperten-
sion (n=9), thrombotic episodes (n=9), and diabetes (n=5). All
patients were treated with cyclosporin A, prednisone, and
azathioprine/mycophenolate-mofetil.
Histological findings
To estimate the number of aSMA-positive host-derived cells in
the graft, we used a real-time PCR assay for the SRY gene. In each
biopsy, host-derived cells accounted for a mean of 3.462.3%
(range, 0.08–12.5%) of aSMA-positive cells obtained by laser
capture microdissection of arterioles. The presence of host-derived
SMCs in the allografts was confirmed by in situ hybridization for
chromosome Y and immunostaining for aSMA (Fig. 1A).
To estimate the extent of rejection, myocardial biopsy samples
were graded for lymphocytic infiltration and necrotic changes as
described [9]. Severe rejection (greater than grade 2) was found in
only 29 (23%) samples. The numbers of arterioles was determined
by staining for aSMA and vWF. During development of
vasculopathy, signs of arteriolitis were visible by edema and
detachment of endothelial cells, decreased staining for aSMA,
luminal narrowing, and changes in morphological structure of
vascular wall (Figure 1B, C). Leukocytes, macrophages, and
lymphocytes were identified by staining for CD45, CD14, CD3,
CD4, and CD8 (Fig. 1D–I). In all biopsies, the number of
infiltrating cells was low but clearly increased with the rejection
grade, as expected. CD45
+ leukocytes were the predominant,
which accumulated in perivascular regions in samples with grade 2
rejection and increased in number with increasing rejection grade.
In grade 3 rejection, these cells also accumulated in areas of
cardiomyocytes. In contrast, CD4
+ and CD8
+ lymphocytes were
detected in perivascular areas and were rare in cardiomyocyte
areas (Fig. 1H, I). As expected, IgG and IgM accumulated with
increasing rejection grade (Fig. 1F, G).
Identifying primary predictors of host-derived SMC
accumulation in the arterioles
To identify factors associated with the accumulation of host-
derived cells around arterioles in the grafts, we built three separate
multiple logistic regression models based on demographic/clinical
factors, cellular characteristic, and biochemical/functional vari-
ables (Table 2).
Demographic and clinical factors. This model included time
from biopsy, age, gender, rejection grade, and coexisting diseases
(Table 1). The presence of host-derived SMCs in the allografts
(Table 2, Fig. 1A) correlated significantly with mean age (40.0620.0
years, p=0.01) (Fig. 1J) and mean rejection grade (1.461.03,
p=0.01). However, several categorical risk factors, including
coexisting diseases and smoking habits, were excluded from the
model because of the low number of patients. Biopsy samples were
obtained 1–70 months (mean, 12.2 months) after transplantation.
Cellular characteristics. In a best-subset logistic regression
analysis, the number of arterioles staining positively for aSMA and
vWF, the number of CD45
+ leukocytes, and rejection grade
independently predicted the accumulation of host-derived SMCs
in the allografts. SMCs were significantly less abundant in areas
with higher numbers of vWF-positive vessels (mean 14.2612.3,
Table 2. Logistic linear regression analysis of factors associated with accumulation of vascular progenitor cells in arterioles.
Predicting factors Mean Median SD Lower quartile 25% Higher quartile 75% p
Demographic
Time from biopsy (mo) 12.238 9 12.472 2 18 0.054
Age (year) 35.990 40 20.008 17.25 52.75 0.010
Rejection grade 1.414 1 1.031 1 2 0.010
Immunohistochemical
aSMA
+ vessels (n) 7.200 7 3.813 5 9 0.013
vWF
+ vessels (n) 14.206 10 10.280 7 17 0.010
CD45
+ cells (n) 19.057 17 12.665 11 24 0.035
CD14
+ cells (n) 12.500 7 15.162 4 16 0.209
CD3
+ cells (n) 16.431 11 13.379 6 25 0.048
CD8
+ cells (n) 5.073 4 4.031 2 7 0.382
CD4
+ cells (n) 7.269 6 4.370 4 10 0.897
Biochemical/functional
Ejection fraction (%) 57.809 57 6.470 53 64 0.445
Hematocrit (%) 33.453 33 3.826 31 36 0.612
Hemoglobin (g/dl) 7.322 7.3 1.022 6.7 7.7 0.035
White blood cells (610
6/l) 7.013 6.45 2.889 4.90 8.22 0.884
Cholesterol (mmol/l) 5.487 5.2 1.909 4.470 6.20 0.724
Triglycerides (mmol/l) 7.027 1.7 43.462 1.180 2.40 0.766
HDL (mmol/l) 2.037 1.5 4.536 1.1900 1.6350 0.645
LDL (mmol/l) 2.966 2.9 0.878 2.20 3.55 0.679
Cyclosporin A (ng/ml) 293.796 265.9 149.682 194.00 374.50 0.010
HDL, high density lipoprotein; LDL, low density lipoprotein.
doi:10.1371/journal.pone.0004187.t002
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host-derived cells increased with the number of CD45
+ leukocytes
(19.1612.7, p=0.035) (Fig. 1K). In a step model, those factors
were the best predictors of increased accumulation of host SMCs
in arterioles (Table 2).
Biochemical and functional parameters. This regression
model included blood morphology, lipid data (e.g., plasma levels of
total cholesterol, high density lipoproteins, and low density
lipoproteins), and plasma concentration of cyclosporin A. Among
functional tests of the heart, only the ejection fraction was included;
data on other parameters were not collected at the time of biopsy.
Hemoglobin and cyclosporin A were associated (p,0.05) with the
accumulation of host-derived SMCs in the graft (Table 2).
Final logistic regression model
The final model, based on results from the partial models,
included the rejection grade, the number of arterioles and CD45
+
leukocytes, hemoglobin levels, and plasma cyclosporin A levels
(Table 3). The number of arterioles was significantly related
(p,0.05) to the number of accumulated SMCs. The number of
host-derived SMCs in arterioles was increased and associated with
the rejection grade (mean 1.4161.03, p=0.034) and the number
of leukocytes (mean 19.06612.66 per 20 HPF, p=0.01).
Cyclosporin A levels correlated inversely with the accumulation
of host-derived SMCs (p=0.14).
MCP-1 is a crucial factor for migration of SMCs
Since the number of leukocytes was associated with increased
accumulation of host-derived SMCs in human cardiac allografts,
we determined whether leukocytes can influence migration of
SMCs. In response to stimulation with leukocyte-conditioned
medium, SMC migration increased by approximately 90% (Fig. 2).
We recently observed that RNA levels of MCP-1, RANTES, and
IP10 are highly increased in aortic allografts. Since MCP-1 is the
major factor for monocyte recruitment to inflamed tissues, we
hypothesized that it might also be involved in the migration of
host-derived SMCs. Indeed, in response to recombinant MCP-1
(50 ng/m), SMC migration increased to levels similar to those
induced by leukocyte-conditioned medium. SMC migration was
inhibited by anti-MCP-1 and anti-CCR2 antibodies added to
leukocyte-conditioned medium (Fig. 2).
To further examine the role of MCP-1 in SMC recruitment to
allografts, we transplanted hearts from Balb mice into B56/c57-
GFP mice. Recipients were treated with anti-MCP-1 antibodies or
isotype control antibodies for 5 days, starting on day 5 after
transplantation. At sacrifice on day 10, the number of host-derived
SMCs and the grade of the inflammatory response in the graft
were assessed by confocal microscopy. Macroscopically, the
control hearts appeared to be more edematous. Microscopic
analysis revealed that anti-MCP-1 treatment significantly de-
creased the number of CD45
+ and CD68
+ leukocytes (Fig. 3A–E),
suggesting a crucial role for MCP-1 in the inflammatory response.
We did not observe a difference in CD3
+, CD8
+, or CD4
+
lymphocytes. Owing to the lower sensitivity of the CD3-specific
antibodies, the number of CD3
+ cells was less than the sum of
CD4
+ and CD8
+ cells. Host-derived cells were mostly present in
small arterioles and were scarce in large arterioles (Fig. 4A, B).
MCP-1 treatment also decreased the number of host-derived SMC
in arterioles (1.5860.53% vs. 0.8960.68% in controls, p,0.05).
Consistent with these findings, immunostaining for MCP-1 in
human cardiac allografts showed that MCP-1 was expressed to a
much greater extent around small arterioles and in areas with
increased cellular inflammation (Fig. 4C). The results further
imply that MCP-1 plays a pivotal role in the accumulation of host-
derived SMCs in cardiac allografts.
Discussion
In this study, we analyzed the accumulation of host-derived
aSMA-positive cells in arterioles in biopsies of human cardiac
allografts. Regression analysis of the clinical data indicated that the
number of host-derived SMCs in arterioles was associated with
acute rejection and the number of infiltrated leukocytes in the
allografts. In vitro, MCP-1 released from leukocytes was crucial for
Table 3. Logistic linear regression analysis of the association
between predicting factors and accumulation of vascular
progenitor cells in arterioles.
Predicting factor Mean Median SD p
Rejection grade 1.41 1 1.03 0.034
aSMA
+ vessels (n) 7.20 7 3.81 0.041
CD45
+ cells (n) 19.06 17 12.66 0.010
Hemoglobin (g/dl) 7.32 7.3 1.02 0.279
Cyclosporin A (ng/ml) 293.78 265.9 149.68 0.143
doi:10.1371/journal.pone.0004187.t003
Figure 2. Migration of SMCs in vitro. SMC migration was induced by leukocyte-conditioned medium and MCP-1 and inhibited by neutralizing
antibodies against MCP-1 and CCR2. *p,0.05.
doi:10.1371/journal.pone.0004187.g002
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MCP-1 was a major factor in SMC recruitment to transplanted
vessels; mice treated with anti-MCP-1 antibodies had significantly
fewer host-derived SMCs in their grafts. These observations
suggest that inflammation and MCP-1 are pivotal in the
recruitment of host-derived SMCs into transplanted organs.
During acute rejection episodes, transplanted grafts exhibit
different grades of inflammation, which lead to apoptotic and
necrotic tissue damage in parallel with the initiation of healing.
During inflammation, leukocytes release proinflammatory cyto-
kines (e.g., interleukins 1a and 6, tumor necrosis factor-a, MCP-1,
stromal cell–derived factor 1, and transforming growth factor b1)
that contribute both to initiation of the inflammation and to
healing [13]. We found signs of acute inflammation and an
increase in the number of host-derived SMC that parallel the
grade of rejection. These findings suggest that inflammation is a
factor in the recruitment of SMCs into transplanted grafts.
Acute rejection has been directly related to cardiac death and to
transplant vasculopathy characterized by occlusive vascular
narrowing due to accumulation and proliferation of SMCs in
the vascular intima, leading to intimal hyperplasia [14]. Previous-
ly, we showed that host-derived SMCs appear in the graft early
after transplantation and start to accumulate within 1 month [10].
Since the number of SMCs was not related to the time between
Figure 3. Immnunohistochemical analysis of mouse cardiac allograft treated anti-MCP-1 or isotypic control. (A and B) Distribution of
CD45
+ leukocytes in cardiac allografts treated with anti-MCP-1 antibodies (A) and control isotypic antibodies (B). (C and D) Distribution of CD68
+
leukocytes in cardiac allografts treated with antibodies against MCP-1 antibodies (C) and control isotypic antibodies (D). Blue, positive signal; red,
nuclear counterstaining. (E) Numbers of aSMA-positive vessels and leukocytes expressing CD45, CD68, CD3, CD4, and CD8. *p,0.05.
doi:10.1371/journal.pone.0004187.g003
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ment is facilitated by other factors, such as immune-mediated
damage of the heart after transplantation [15].
Indeed, the number of accumulated host-derived cells in the
graft correlated strongly with the number of CD45
+ leukocytes
and the grade of rejection, confirming that inflammation is
strongly related to the recruitment of host-derived cells into the
graft vessels. In support of this hypothesis, we previously found
that an allogenic response in rats leads to apoptosis of transplanted
SMCs that may affect the survival of host-derived cells that
migrate to the transplanted vessels [10]. We have also shown that
an immunosuppression regimen can protect the allograft from
damage and reduce the recruitment of host-derived cells [16].
Transplant recipients with lower rejection grades or no acute
rejection episodes have a lower risk of late chronic rejection and in
particular transplant vascular sclerosis [17]. Thus, inflammation
may be an underestimated cause for increased recruitment of
progenitor cells to injured tissue to initiate vascular repair.
In studies to identify the inflammatory factors involved in the
migration of SMCs in vitro, we found that SMCs migrated in
response to leukocyte-conditioned medium and that MCP-1 and
its receptor CCR2 were major factors in that migration. In vivo,
MCP-1 and CCR2 played a pivotal role in recruiting SMCs into
heterotopic heart grafts in mice. These observations support a
crucial role for MCP-1 and CCR2 in the recruitment of vascular
progenitor cells, perhaps to assist in healing. Indeed, MCP-1 is
thought to contribute to healing of vascular injury [18] by
recruiting vascular progenitor cells [19]. In atherosclerosis, MCP-1
is involved in recruitment of monocytes/macrophages into the
vascular wall and in the formation of lipid cores and atheroscle-
rotic plaques [20].
Other nonspecific risk factors for transplant vasculopathy,
including smoking, hypertension, and coronary artery disease,
did not correlate significantly with the number of host-derived
SMCs in the vascular wall, perhaps because of the small numbers
of patients with those risk factors. Reduction of circulating
endothelial progenitor cells in the blood seems to be related to
the level of vascular damage [21–24]. Moreover, factors such as
hypertension and diabetes appear to impair the migration of
endothelial progenitor cells [24]. Vascular progenitor cells appear
to be specifically recruited into injured tissues, but the factors
leading to their recruitment and their functions in the healing of
tissue damage are poorly understood [25,26]. The physiological
status of arteries in these diseases affects the number of circulating
progenitors by influencing their maturation, release from the bone
marrow, and accumulation in injured tissues [27–29]. Thus,
inflammation may lead to the recruitment of these cells. However,
our findings do not indicate the source of host-derived SMCs and
vascular progenitors.
In summary, we provide evidence that inflammation and MCP-
1 are pivotal in the recruitment of host-derived SMCs into
transplanted hearts. This knowledge may be useful in designing
protocols aimed at reducing the number of host-derived SMC in
cardiac allografts and increasing the number of progenitor cells to
limit tissue damage and facilitate healing at sites of tissue injury.
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